European Association of Urology

Company

Related News

64Cu-SAR-bisPSMA PET/CT Doubles Prostate Cancer Lesion Detection vs 68Ga-PSMA-11 in Phase 2 Trial

May 16, 2026

Phase 2 Co-PSMA trial shows 64Cu-SAR-bisPSMA PET/CT detected 63 prostate cancer lesions vs 24 with 68Ga-PSMA-11, with 78% vs 36% positive scans. Results changed management in 44% of patients.

ImmunityBio Receives EU Authorization for ANKTIVA Bladder Cancer Treatment

Feb 14, 2026

The European Commission granted conditional marketing authorization for ANKTIVA plus BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, marking the first approved immunotherapy for this indication in Europe.